Jimmy Carter's cancer treatment 'going well'

Former United States president Jimmy Carter is reported to be responding well to cancer treatment.
Former United States president Jimmy Carter is reported to be responding well to cancer treatment. PHOTO: REUTERS

ATLANTA • Former United States president Jimmy Carter is reported to be responding well to cancer treatment and there is no evidence of new malignancy.

Mr Carter, 91, started treatment in August for melanoma that had spread from his liver to his brain. The Nobel peace laureate and global humanitarian recently had a tumour from his liver removed, only to find four melanoma spots on his brain.

After recent tests, doctors carrying out radiation treatment at Emory University's Winship Cancer Institute gave Mr Carter the "good news" on Tuesday, said the Carter Centre, a policy centre founded by the former president.

Mr Carter was planning to travel to Nepal this month on a home- building trip with non-profit group Habitat for Humanity, but the trip was cancelled because of "civil unrest" in the country. Mr Carter participated in a Habitat home-building event in Memphis, Tennessee, last week, the Carter Centre said.

Mr Carter, a one-time peanut farmer, served one term in office from 1977 to 1981. He played a key role in Middle East peace negotiations during his presidency. He won the Nobel Peace Prize in 2002.

The former Democratic president won plaudits when he discussed his illness publicly in August, sounding serene and in high spirits, smiling often and joking with reporters in a thick Georgia drawl. "You know, I have had a wonderful life. I have got thousands of friends and I have had an exciting and adventurous and gratifying existence," he said.

Several of Mr Carter's relatives died of pancreatic cancer, but that tends to show up earlier in life.

REUTERS, AGENCE FRANCE-PRESSE

A version of this article appeared in the print edition of The Straits Times on November 12, 2015, with the headline 'Jimmy Carter's cancer treatment 'going well''. Print Edition | Subscribe